1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Ascletis Inc. - Product Pipeline Review - 2014

Ascletis Inc. - Product Pipeline Review - 2014

  • November 2014
  • -
  • Global Markets Direct
  • -
  • 29 pages

Ascletis Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Ascletis Inc. - Product Pipeline Review - 2014’, provides an overview of the Ascletis Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ascletis Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Ascletis Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Ascletis Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Ascletis Inc.’s pipeline products

Reasons to buy

- Evaluate Ascletis Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Ascletis Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Ascletis Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Ascletis Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ascletis Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Ascletis Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Ascletis Inc. - Product Pipeline Review - 2014
Table of Contents

Ascletis Inc. Snapshot 4
Ascletis Inc. Overview 4
Key Information 4
Key Facts 4
Ascletis Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Ascletis Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Partnered Products 9
Partnered Products/Combination Treatment Modalities 10
Ascletis Inc. - Pipeline Products Glance 11
Ascletis Inc. - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Ascletis Inc. - Early Stage Pipeline Products 12
Discovery Products/Combination Treatment Modalities 12
Ascletis Inc. - Drug Profiles 13
danoprevir 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
PPI-668 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
TMC-310911 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
ASC-01 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Ascletis Inc. - Pipeline Analysis 19
Ascletis Inc. - Pipeline Products by Target 19
Ascletis Inc. - Pipeline Products by Route of Administration 20
Ascletis Inc. - Pipeline Products by Molecule Type 21
Ascletis Inc. - Pipeline Products by Mechanism of Action 22
Ascletis Inc. - Recent Pipeline Updates 23
Ascletis Inc. - Dormant Projects 26
Ascletis Inc. - Locations And Subsidiaries 27
Head Office 27
Other Locations and Subsidiaries 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 29
Disclaimer 29

List of Tables

Ascletis Inc., Key Information 4
Ascletis Inc., Key Facts 4
Ascletis Inc. - Pipeline by Indication, 2014 6
Ascletis Inc. - Pipeline by Stage of Development, 2014 7
Ascletis Inc. - Monotherapy Products in Pipeline, 2014 8
Ascletis Inc. - Partnered Products in Pipeline, 2014 9
Ascletis Inc. - Partnered Products/ Combination Treatment Modalities, 2014 10
Ascletis Inc. - Phase II, 2014 11
Ascletis Inc. - Discovery, 2014 12
Ascletis Inc. - Pipeline by Target, 2014 19
Ascletis Inc. - Pipeline by Route of Administration, 2014 20
Ascletis Inc. - Pipeline by Molecule Type, 2014 21
Ascletis Inc. - Pipeline Products by Mechanism of Action, 2014 22
Ascletis Inc. - Recent Pipeline Updates, 2014 23
Ascletis Inc. - Dormant Developmental Projects,2014 26
Ascletis Inc., Other Locations 27

List of Figures

Ascletis Inc. - Pipeline by Top 10 Indication, 2014 6
Ascletis Inc. - Pipeline by Stage of Development, 2014 7
Ascletis Inc. - Monotherapy Products in Pipeline, 2014 8
Ascletis Inc. - Pipeline by Top 10 Target, 2014 19
Ascletis Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, ...

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) ...

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016’, ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.